Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

Core Viewpoint - Catalyst Pharmaceuticals has entered into a Settlement Agreement with Teva Pharmaceuticals to resolve patent litigation regarding the generic version of FIRDAPSE, ensuring that Teva cannot market its generic version before February 25, 2035, if approved by the FDA [1][2]. Company Overview - Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with a commitment to patient care and accessibility [4]. - The company has a strong presence in the U.S. and is actively seeking to expand its global footprint through strategic partnerships [4]. - Catalyst was recognized as one of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List [4]. Legal and Regulatory Aspects - The Settlement Agreement will terminate all ongoing patent litigation between Catalyst/SERB and Teva regarding FIRDAPSE patents in the U.S. District Court for the District of New Jersey [2]. - The confidential license agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice for review as required by law [3].